Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Johannson, K., Strâmbu, I., Ravaglia, C., Grutters, J., Valenzuela, C., Mogulkoc, N., et al. (2017). Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. THE LANCET RESPIRATORY MEDICINE, 5(7), 591-598 [10.1016/S2213-2600(17)30219-9].

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Luppi, Fabrizio;Harari, Sergio;
2017

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
Articolo in rivista - Articolo scientifico
Antacids; Disease Progression; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Idiopathic Pulmonary Fibrosis; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Severity of Illness Index; Pulmonary and Respiratory Medicine
English
2017
5
7
591
598
reserved
Johannson, K., Strâmbu, I., Ravaglia, C., Grutters, J., Valenzuela, C., Mogulkoc, N., et al. (2017). Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. THE LANCET RESPIRATORY MEDICINE, 5(7), 591-598 [10.1016/S2213-2600(17)30219-9].
File in questo prodotto:
File Dimensione Formato  
Johannson KI et al. Lancer Respir Med. 2017.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 201.49 kB
Formato Adobe PDF
201.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/219312
Citazioni
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 66
Social impact